RxDoctor Payments DataLook up a doctor →

Robert Muldoon, MD

Hematology & Oncology · Hot Springs, ARNPI 1841277589

Payments from drug & device makers

$87,984in general payments, 2019–2025

Across 1,051 payments — averaging $83.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AVEO Pharmaceuticals, Inc.$50K
  • Merck$22K
  • AstraZeneca$2K
  • Novartis$1K
  • Pfizer$1K
  • Gilead$713
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$16,55299%
  • Education$1961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AVEO Pharmaceuticals, Inc.33$50,115
Merck49$21,962
AstraZeneca(2 entities)85$1,575
Novartis97$1,444
Pfizer83$1,262
Gilead(2 entities)36$713
Bristol Myers Squibb56$618
Lilly USA, LLC40$600
GSK36$585
Johnson & Johnson(2 entities)33$577
Exelixis Inc.33$573
Eisai Inc.35$561
E.r. Squibb & Sons, L.L.C.42$511
Incyte Corporation25$447
Seagen Inc.22$339
Sanofi18$337
Daiichi Sankyo Inc.17$331
AbbVie19$326
Amgen22$325
Bayer18$317
Genentech USA, Inc.21$291
Astellas Pharma US Inc16$274
Pharmacyclics LLC, An Abbvie Company16$261
Takeda Pharmaceuticals U.S.A., Inc.12$241
Servier Pharmaceuticals LLC3$202
Array Biopharma Inc11$196
Karyopharm Therapeutics Inc.11$189
EMD Serono, Inc.11$173
Clovis Oncology, Inc.10$147
Puma Biotechnology, Inc.9$143
Morphosys, US Inc.7$133
Regeneron Healthcare Solutions, Inc.6$129
Dendreon Pharmaceuticals LLC5$128
Myovant Sciences Inc.7$122
Beigene USA, Inc.7$112
Boehringer Ingelheim5$108
Rigel Pharmaceuticals, Inc.7$106
Sobi, Inc6$105
Ipsen Biopharmaceuticals, Inc5$88
AMAG Pharmaceuticals, Inc.5$82
ADC Therapeutics America, Inc.4$77
Tesaro, Inc.4$76
Epizyme, Inc.5$75
Pharmacosmos Therapeutics Inc.5$69
Pharmaessentia USA Corporation4$64
Shield Therapeutics Inc4$63
Beone Medicines USA, Inc.3$61
Geron Corporation3$60
Blueprint Medicines Corporation2$59
Myriad Genetic Laboratories, Inc.3$56
Dova Pharmaceuticals3$51
Agios Pharmaceuticals, Inc.3$42
Sumitomo Pharma America, Inc.2$36
Celltrion USA Inc.2$33
Taiho Oncology, Inc.2$33
Spectrum Pharmaceuticals Inc.2$32
G1 Therapeutics, Inc.2$31
Jazz Pharmaceuticals Inc.2$30
Tempus AI, Inc1$30
Genmab U.S., Inc.2$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$87,984 in reported general payments places this provider in the 70th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$8,657,048
Medicare patients
1,257
Services billed
368,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate49$680,996
XtandiEnzalutamide34$451,011
OjjaaraMomelotinib Dihydrochloride13$357,017
BrukinsaZanubrutinib23$335,803
ZejulaNiraparib Tosylate11$202,609
LynparzaOlaparib12$195,336
ErleadaApalutamide13$183,607
NubeqaDarolutamide11$148,621
KisqaliRibociclib Succinate12$134,734
ZarxioFilgrastim-Sndz75$133,729
CalquenceAcalabrutinib Maleate12$129,670
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5020$125,193
EliquisApixaban50$37,124
Abiraterone Acetate12$21,933
XareltoRivaroxaban22$16,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$447$680,99649 claims
GSKOjjaara, Zejula$585$559,62624 claims
Astellas Pharma US IncXtandi$274$451,01134 claims
Beigene USA, Inc.Brukinsa$112$335,80323 claims
AstraZenecaLynparza, Calquence$1,575$325,00624 claims
Johnson & JohnsonErleada, Xarelto$577$199,89635 claims
BayerNubeqa$317$148,62111 claims
NovartisKisqali$1,444$134,73412 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$241$125,19320 claims
PfizerEliquis$1,262$37,12450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →